Begins Coverage on Brainstorm Cell Therapeutics (NASDAQ:BCLI) started coverage on shares of Brainstorm Cell Therapeutics (NASDAQ:BCLIFree Report) in a research report released on Wednesday. The firm issued a hold rating on the biotechnology company’s stock.

Brainstorm Cell Therapeutics Trading Down 4.3 %

NASDAQ:BCLI opened at $0.37 on Wednesday. Brainstorm Cell Therapeutics has a 12 month low of $0.13 and a 12 month high of $2.44. The stock has a market capitalization of $25.93 million, a price-to-earnings ratio of -1.16 and a beta of 0.43. The firm has a fifty day simple moving average of $0.48 and a two-hundred day simple moving average of $0.41.

Brainstorm Cell Therapeutics (NASDAQ:BCLIGet Free Report) last issued its earnings results on Tuesday, May 14th. The biotechnology company reported ($0.05) EPS for the quarter, beating analysts’ consensus estimates of ($0.07) by $0.02. Equities analysts predict that Brainstorm Cell Therapeutics will post -0.28 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Brainstorm Cell Therapeutics

A hedge fund recently bought a new stake in Brainstorm Cell Therapeutics stock. Kingswood Wealth Advisors LLC bought a new position in Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLIFree Report) in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 81,050 shares of the biotechnology company’s stock, valued at approximately $46,000. Kingswood Wealth Advisors LLC owned about 0.12% of Brainstorm Cell Therapeutics at the end of the most recent reporting period. 14.33% of the stock is currently owned by institutional investors.

Brainstorm Cell Therapeutics Company Profile

(Get Free Report)

Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.

Featured Stories

Receive News & Ratings for Brainstorm Cell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brainstorm Cell Therapeutics and related companies with's FREE daily email newsletter.